


**Figure 1:** Clinician decision on duration and type of dual anti-platelet therapy by risk group.



**Table 1:** Baseline demographics, clinical features and relevant investigations.

Demographic	Frequency (n=100)
Age (SD), year	63.4 (12.3)
Male	73
Ethnicity	
European	39
New Zealand Māori	7
Pacific peoples	25
Indian	15
Chinese/Other Asian	14
New Zealand Index of Deprivation (SD), (quintile)	3.5 (1.5)
Quintile 1	16
Quintile 2	18
Quintile 3	15
Quintile 4	17
Quintile 5	34

**Table 1 (continued):** Baseline demographics, clinical features and relevant investigations.

Heart rate (bpm)	91 (15)
Estimated GFR <sup>1</sup> (SD), (mL/min/1.73m <sup>2</sup> )	69.4 (24.4)
Haemoglobin level (SD), units	157 (15.3)
Low Hb <sup>2</sup>	17
Coronary artery disease severity	
Single vessel disease	74
Double vessel disease	23
Triple vessel disease or LMS	3
History of CVD <sup>3</sup>	
No prior CVD	73
Prior MI	26
Other prior CVD	1
Diabetes mellitus	33
With insulin	13
Current smoker	18
Type of ACS <sup>4</sup>	
NSTEMI <sup>5</sup>	57
STEMI <sup>6</sup>	29
Unstable angina	14
Worst Killip class in hospital	1 (0.5)
I	92
II-IV	8
Left ventricular ejection fraction	
Normal (≥50%)	61
Mid-range (40–49%)	18
Reduced (<40%)	17
Prior hospitalisation for bleeding	2
Index admission bleeding	1
Total: HDL cholesterol ratio	4.5 (1.8)

<sup>1</sup>Glomerular filtration rate

<sup>2</sup>Low haemoglobin: Hb <115g/L for women, <130g/L for men

<sup>3</sup>Cardiovascular disease

<sup>4</sup>Acute Coronary Syndrome


<sup>5</sup>Non-ST Elevation Myocardial Infarction

<sup>6</sup>ST Elevation Myocardial Infarction


**Table 2:** Duration of planned dual anti-platelet therapy by risk group.

Second anti-platelet	Duration (months)	Low I, low B	Low I, high B	High I, low B	High I, high B
Clopidogrel	6	1	3	1	3
	12	1	0	3	10
Ticagrelor	1	1	0	0	0
	3	0	0	0	1
	6	0	0	0	0
	6-12	0	0	0	1
	12	24	6	16	29
<b>Total</b>		27	9	20	44

**Figure 2:** Percentage of patients planned for guideline recommended duration of dual anti-platelet therapy according to ischaemic and bleeding risk categories.



**Figure 3:** Bleeding versus ischaemic risk.



**Table 3:** Choice of proton pump inhibitor.

	Choice of PPI	Number of patients
<b>Clopidogrel</b>	Lansoprazole	1
	Omeprazole	3
	Pantoprazole	15
	No PPI	3
	Total	22
<b>Ticagrelor</b>	Lansoprazole	0
	Omeprazole	60
	Pantoprazole	12
	No PPI	6
	Total	78